Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation

Archives of Internal Medicine

Volumn 161, Issue 17, 2001, Pages 2125-2128

  Copland, Mhairi ^a,b   Walker, Isobel D ^a   Tait, R Campbell ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PLACEBO; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; DRUG EFFICACY; ELDERLY CARE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; STROKE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL EMBOLISM; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME; WARFARIN;

EID: 0035944374     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.17.2125     Document Type: Article

References (14)

1. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention [review]. Ann Intern Med. 1999;131:688-695.
2. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
3. Peterson P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-179.
4. The Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
5. The Boston Area Anticoagulant Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk for stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
6. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
7. Ezekowitz MD, Bridgers SL, James KE, et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
8. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention of in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
9. Hart RG. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation [letter]. Ann Intern Med. 1998;128:408.
10. Wheeldon NM. Atrial fibrillation and anticoagulation therapy [review]. Eur Heart J. 1995;16:302-312.
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
12. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
13. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ. 2000;320:1236-1239.
14. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention [review]. Am J Med. 1993;95:315-328.